Skip to main content
Livermore
Livermore
ZHEN

D. E. Shaw & Co., Inc.

SEC CIK
0001009207
Latest filing
Aug 14, 2026

HALO holding history

Halozyme Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

HALO overviewAll 13F holders of HALOFull Q2 2026 holdings

Shares (Q2 2026)
2,006,479
Value
$157.0M
% of portfolio
0.1%
Quarters held
22
Since Q1 2021
Holdings of HALO by D. E. Shaw & Co., Inc., by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20262,006,479$157.0M0.1%+137,771+7.4%AddedHolders
Q1 20261,868,708$120.8M0.1%+219,242+13.3%AddedHolders
Q4 20251,649,466$111.0M0.1%−1,000,909−37.8%ReducedHolders
Q3 20252,650,375$194.4M0.2%+1,631,571+160.1%AddedHolders
Q2 20251,018,804$53.0M0.1%+399,242+64.4%AddedHolders
Q1 2025619,562$39.5M<0.1%−211,852−25.5%ReducedHolders
Q4 2024831,414$39.7M<0.1%+524,802+171.2%AddedHolders
Q3 2024306,612$17.6M<0.1%−172,163−36.0%ReducedHolders
Q2 2024478,775$25.1M<0.1%+180,650+60.6%AddedHolders
Q1 2024298,125$12.1M<0.1%+272,549+1,065.6%AddedHolders
Q4 202325,576$945.3K<0.1%+3,527+16.0%AddedHolders
Q3 202322,049$842.3K<0.1%+10,849+96.9%AddedHolders
Q2 202311,200$404.0K<0.1%−15,686−58.3%ReducedHolders
Q1 202326,886$1.03M<0.1%−3,499−11.5%ReducedHolders
Q4 202230,385$1.73M<0.1%+3,368+12.5%AddedHolders
Q3 202227,017$1.07M<0.1%+2,917+12.1%AddedHolders
Q2 202224,100$1.06M<0.1%−10,573−30.5%ReducedHolders
Q1 202234,673$1.38M<0.1%−193,434−84.8%ReducedHolders
Q4 2021228,107$9.17M<0.1%+1,796+0.8%AddedHolders
Q3 2021226,311$9.21M<0.1%−211,087−48.3%ReducedHolders
Q2 2021437,398$19.9M<0.1%−431,065−49.6%ReducedHolders
Q1 2021868,463$36.2M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.